Clinical significance of serum p53 antibody in patients with gastric cancer

Research Communications in Molecular Pathology and Pharmacology

Volumn 99, Issue 1, 1998, Pages 41-51

  Shiota, Goshi ^a   Ishida, Masato ^a   Noguchi, Naoya ^a   Takano, Yuji ^a   Oyama, Kenji ^a   Okubo, Michiko ^a   Katayama, Shunsuke ^a   Harada, Kenichi ^a   Hori, Kotaro ^a   Ashida, Kumiyo ^a   Kishimoto, Yosuke ^a   Hosoda, Akihide ^a   Suou, Takeaki ^a   Ito, Hisao ^a   Kawasaki, Hironaka ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; STOMACH POLYP;

ADENOMA; AGED; ANTIBODIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; POLYPS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031888850     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Angelpoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP (1996). Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 78:2146-2152.
2. Brito MJ, Williams GT, Thomson H, Filipe MI (1994) Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut 35:1697-1700.
3. Crawford LV, Pim DC, Bulbrook RD (1982) Detection of antibodies against cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403-408.
4. Caron De Fronmentel C, May-Levin F, Mouriesse H, Chandrasekaran K, May P (1987) Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 39:185-189.
5. Davidoff AM, Iglehart JD, Marks JR (1992) Immune response to p53 is dependent on p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89:6380-6384.
6. Fonseca L, Yonemura Y, De Aretxabala X, Yamaguchi A, Miwa K, Miyazaki I (1994) p52 detection as a prognostic factor in early gastric cancer. Oncol. 51:485-490.
7. Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G (1995) The relationship of p53 expression of 418 patients with gastric carcinoma. Cancer 76:720-726.
8. Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produces a common conformational effect - a monoclonal antibody specific for the mutant form. EMBO J 9:1595-1623.
9. Gomyo Y, Osaki M, Kaibara N, Ito H (1996) Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int J Cancer 66:594-599.
10. Ishida M, Gomyo Y, Ohfuji S, Ikeda M, Ito H, Kawasaki H (1997) Evidence that expression of a mutated p53 gene attenuates apoptotic cell death in human gastric intestinal-type carcinoma in vitro. (Jpn J Cancer Res in press).
11. Joypaul BV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cuschieri A (1993) Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. J Pathol 170:279-283.
12. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP, Cuschieri A (1994) The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69:943-946.
13. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K (1993) Gastric cancer with p53 over-expression has high potential for metastasizing to lymph nodes. Br J Cancer 67:589-593.
14. Levine AJ, Momand A, Finlay CA (1992) The p53 tumor suppressor gene. Nature 358:453-456.
15. Lubin R, Sclichtholz RLB, Bengoufa D, Zalcman BG, Tredaniel J, Hirsch A, Caron de Fronmental C, Preudhomme C, Fenaux P, Fournier G, Margin P, Laurent-Puig P, Pelletir G, Schlumberger M, Desgrandchamps F, Duc AL, Peyrat JP, Janin N, Bressac B, Soussi T (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface. Cancer Res 53:5872-5876.
16. Muller W and Borchard F (1996) Prognostic influence of p53 expression in gastric cancer. J Pathol 178:255-258.
17. Ochiai A, Yamauchi Y, Hirohashi S (1996) p532 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer 69:28-33.
18. Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K (1995) Growth pattern and p53 over-expression in patients with gastric cancer. Cancer 75:12454-1459.
19. Peyrat J-P, Bonnetterre J, Lubin R, Vanlemmens L, Fournir J, Souussi T (1995) Prognostic significance of circulating p53 antibodies in patients undergoing surgery for coloregional breast cancer. Lancet 345:621-622.
20. Sakurai S, Sano T, Nakajima T (1995) Clinicopathological and molecular biological studies of gastric adenomas with special reference to p53 abnormality. Pathol Int 45:51-57.
21. Sclichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380-6384.
22. Tahara E, Senba S, Tahara H (1996) Molecular biological observation in gastric cancer. Semin Oncol 23:307-315.
23. Triantafillou NG, Grosman IM, Verma RS (1996) Genomania of p53 protein in gastric cancer. J Clin Gastroenterol 22:170-173.
24. UICC:TNM Classification of Malignant Tumors (1993) Stomach (ICD-O151). In: The General Rules for the Gastric Cancer Study, Fourth Edition, Kinbara and Co., Ltd. Tokyo, pp147-150.
25. Volkmann M, Müller M, Hoffman WJ, Meyer M, Hagelstein J, Räth U, Kommerrell B, Zentgraf H, Galle PR (1993) The humoral immune response to p53 in patients with hepatocellular carcinoma is specific and independent of the a fetoprotein. Hepatology 18:559-565.
26. Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ (1996) Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 32A: 215-220.
27. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168-4174.